MannKind Corporation (NASDAQ:MNKD) most recently reported quarterly actual earnings per share of $-0.07 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-0.05. The difference between the estimate and the actual EPS was $-0.02 creating a surprise factor of -40%. Currently, the company has an impact score of 89. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.203. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $0.15 on the shares. The most bullish brokerage firm has a $0.2 target, while the most bearish sees the stock headed towards $0.1. This is according to the 2 estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 5. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 2 recommendations taking into account in order to arrive at this number. Of the 2, 0 have a Strong Buy rating and 0 are rating it a Buy.

MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company’s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia. The AFREZZA inhalation powder is centered on a class of potential of hydrogen (pH)-sensitive organic molecules. AFREZZA utilizes its Technosphere formulation technology. As of December 31, 2011, MannKind had not generated any product revenues. As of December 31, 2011, the AFREZZA clinical program had involved 61 different studies of AFREZZA and over 5,600 adult patients.

MannKind Corporation - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.